Free Trial

SVB Securities' Rating of Arrowhead Pharmaceuticals on 5/12/2023

On May 12, 2023, SVB Securities updated its outlook on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with the action "Downgrade", setting a "Market Perform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.